Income Statement Cuorips Inc.

Equities

4894

JP3266030000

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-09-09 am EDT			5-day change	1st Jan Change
7,540.00 ^JPY	+3.43%		-5.51%	+224.86%

2023	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023.	CI
2023	Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023.	CI

8d651be5eaa45990d715849df737.mytvA2L3MjWsnLBM8OPUXyCwLK3iNWM1GUhlmYcVe-I.8RI7XA-OfHzppecigoKdPHLFHt2VYTkNIQYT08tCLYWjTxliCYBAXJXD6Q

Published financial data: CUORIPS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2021	2022	2023
Revenues	-	13M	38M
Total Revenues	-	13M	38M
Cost of Goods Sold, Total	-	3M	17M
Gross Profit	-	10M	21M
Selling General & Admin Expenses, Total	281M	383M	471M
Other Operating Expenses, Total	281M	383M	471M
Operating Income	-281M	-373M	-450M
Other Non Operating Income (Expenses)	-15M	-	-
EBT, Excl. Unusual Items	-296M	-373M	-450M
EBT, Incl. Unusual Items	-296M	-373M	-450M
Income Tax Expense	11M	2M	2M
Earnings From Continuing Operations	-307M	-375M	-452M
Net Income to Company	-307M	-375M	-452M
Net Income - (IS)	-307M	-375M	-452M
Net Income to Common Incl Extra Items	-307M	-375M	-452M
Net Income to Common Excl. Extra Items	-307M	-375M	-452M
Per Share Items
Net EPS - Basic	-123.32	-66.54	-79.89
Basic EPS - Continuing Operations	-123.32	-66.54	-79.89
Basic Weighted Average Shares Outstanding	2.49M	5.64M	5.66M
Net EPS - Diluted	-123.32	-66.54	-79.89
Diluted EPS - Continuing Operations	-123.32	-66.54	-79.89
Diluted Weighted Average Shares Outstanding	2.49M	5.64M	5.66M
Normalized Basic EPS	-74.31	-41.37	-49.71
Normalized Diluted EPS	-74.31	-41.37	-49.71
Supplemental Items
EBITA	-281M	-373M	-450M
EBIT	-281M	-373M	-450M
Effective Tax Rate - (Ratio)	-3.72	-0.54	-0.44
Normalized Net Income	-185M	-233M	-281M

Fiscal Period: March	2021	2022	2023
Assets
Cash And Equivalents	3.54B	3.34B	2.94B
Total Cash And Short Term Investments	3.54B	3.34B	2.94B
Accounts Receivable, Total	-	1M	2M
Other Receivables	56M	-	-
Total Receivables	56M	1M	2M
Inventory	-	-	4M
Prepaid Expenses	17M	16M	14M
Other Current Assets, Total	3M	9M	16M
Total Current Assets	3.62B	3.37B	2.98B
Net Property Plant And Equipment	701M	633M	562M
Long-term Investments	44M	43M	42M
Other Intangibles, Total	-	-	5M
Other Long-Term Assets, Total	1M	1M	1M
Total Assets	4.36B	4.04B	3.59B
Liabilities
Accrued Expenses, Total	3M	-	-
Current Income Taxes Payable	80M	45M	57M
Other Current Liabilities	21M	67M	40M
Total Current Liabilities	104M	112M	97M
Deferred Tax Liability Non Current	9M	8M	8M
Other Non Current Liabilities	29M	30M	29M
Total Liabilities	142M	150M	134M
Common Stock, Total	100M	10M	10M
Additional Paid In Capital	4.78B	4.9B	4.91B
Retained Earnings	-642M	-1.02B	-1.47B
Treasury Stock	-18M	-16M	-11M
Comprehensive Income and Other	-1M	13M	15M
Total Common Equity	4.22B	3.89B	3.45B
Total Equity	4.22B	3.89B	3.45B
Total Liabilities And Equity	4.36B	4.04B	3.59B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2.49M	5.64M	5.66M
ECS Total Common Shares Outstanding	2.49M	5.64M	5.66M
Book Value / Share	1.7K	690.96	610
Tangible Book Value	4.22B	3.89B	3.45B
Tangible Book Value Per Share	1.7K	690.96	609.12
Total Debt	0	0	0
Net Debt	-3.54B	-3.34B	-2.94B

Fiscal Period: March	2021	2022	2023
Supplemental Items
Change In Net Working Capital	-	-58M	25M

Fiscal Period: March	2021	2022	2023
Profitability
Return on Assets	-	-5.55	-7.37
Return on Total Capital	-	-5.74	-7.66
Return On Equity %	-	-9.24	-12.3
Return on Common Equity	-	-9.24	-12.3
Margin Analysis
Gross Profit Margin %	-	76.92	55.26
SG&A Margin	-	2.95K	1.24K
EBITA Margin %	-	-2.87K	-1.18K
EBIT Margin %	-	-2.87K	-1.18K
Income From Continuing Operations Margin %	-	-2.88K	-1.19K
Net Income Margin %	-	-2.88K	-1.19K
Net Avail. For Common Margin %	-	-2.88K	-1.19K
Normalized Net Income Margin	-	-1.79K	-740.13
Asset Turnover
Asset Turnover	-	0	0.01
Fixed Assets Turnover	-	0.02	0.06
Receivables Turnover (Average Receivables)	-	-	25.33
Short Term Liquidity
Current Ratio	34.79	30.06	30.69
Quick Ratio	34.6	29.84	30.34
Days Sales Outstanding (Average Receivables)	-	-	14.41
Long Term Solvency
Total Liabilities / Total Assets	3.25	3.71	3.74
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-	192.31
Gross Profit, 1 Yr. Growth %	-	-	110
EBITA, 1 Yr. Growth %	-	32.74	20.64
EBIT, 1 Yr. Growth %	-	32.74	20.64
Earnings From Cont. Operations, 1 Yr. Growth %	-	22.15	20.53
Net Income, 1 Yr. Growth %	-	22.15	20.53
Normalized Net Income, 1 Yr. Growth %	-	26.01	20.64
Diluted EPS Before Extra, 1 Yr. Growth %	-	-46.04	20.06
Accounts Receivable, 1 Yr. Growth %	-	-	100
Net Property, Plant and Equip., 1 Yr. Growth %	-	-9.7	-11.22
Total Assets, 1 Yr. Growth %	-	-7.33	-11.3
Tangible Book Value, 1 Yr. Growth %	-	-7.77	-11.45
Common Equity, 1 Yr. Growth %	-	-7.77	-11.33
Compound Annual Growth Rate Over Two Years
EBITA, 2 Yr. CAGR %	-	-	26.55
EBIT, 2 Yr. CAGR %	-	-	26.55
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	21.34
Net Income, 2 Yr. CAGR %	-	-	21.34
Normalized Net Income, 2 Yr. CAGR %	-	-	23.3
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	-19.51
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	-10.46
Total Assets, 2 Yr. CAGR %	-	-	-9.34
Tangible Book Value, 2 Yr. CAGR %	-	-	-9.63
Common Equity, 2 Yr. CAGR %	-	-	-9.56